Literature DB >> 28217163

Pediatric central neurocytoma: Case report and review of literature.

Basanta Kumar Baishya1, Rishi Kant Singh1, Deep Dutta1, Zakir Hussain1.   

Abstract

Central neurocytomas are slow-growing primary brain tumors of neuronal origin having a predilection to arise mostly in the lateral ventricles. We report a case of a 9-year-old girl who presented with headache and vomiting of 1-month duration. Her magnetic resonance imaging was suggestive of central neurocytoma of the third ventricle and was surgically managed, and tumor tissue was sent for histopathology and immunohistochemistry which confirmed the diagnosis.

Entities:  

Keywords:  Central neurocytoma; immunohistochemistry; synaptophysin

Year:  2016        PMID: 28217163      PMCID: PMC5314854          DOI: 10.4103/1817-1745.199485

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


Introduction

Central neurocytomas are slow-growing neuronal primary intracranial tumors, found mostly in young adults, usually located in the lateral ventricles.[12] Pediatric presentation of central neurocytoma is very rare, and no significant data have been published regarding their incidence. Rades et al. in their series of neurocytoma in children reviewed 59 patients, which is so far considered the largest case series of this rare neoplasm of children under 18 years, reported only 13 (22%) patients who were in the first decade.[3] We are reporting this case because of its rarity, especially in this age and its location. Our case is of a 9–year-old girl who was diagnosed with central neurocytoma of the third ventricle.

Case Report

A 9-year-old previously healthy girl presented with headache of 1-month duration, which was continuous and holocranial in nature. There was also associated nausea and several episodes of vomiting for the past 1 month. On detailed clinical examination, the only positive finding was mild bilateral papilledema. The vital signs were within normal limits, and there were no focal neurological deficits. Her blood reports were unremarkable. On magnetic resonance imaging of the brain, a well-defined globular mass with mixed intensity was noted within the third ventricle, thereby causing its distension. The tumor measured 47 mm × 59 mm × 55 mm in craniosacral and craniocaudal dimensions. Bilateral thalamic compression was noted along with upstream hydrocephalus. On T2 imaging [Figure 1b], the mass appeared heterogeneously hyperintense, and on T1-weighted [Figure 1a], a hyperintense area with multiple cystic areas was noted. The solid part of the lesion showed diffusion restriction. Postcontrast the tumor showed enhancement [Figure 1c]. Magnetic resonance spectroscopy revealed high choline and glycine peaks with low N-acetylaspartate peaks.
Figure 1

(a) T1 axial section of brain showing a hyperintense lesion with multiple cystic areas within the third ventricle. Mild dilatation of lateral ventricles is seen. (b) T2 axial section of the brain showing a heterogeneously hyperintense lesion in the third ventricle. Multiple intratumoral cysts resembling “soap bubble” are seen. (c) Sagittal section of brain on contrast study showing intense enhancement of the solid part of the lesion

(a) T1 axial section of brain showing a hyperintense lesion with multiple cystic areas within the third ventricle. Mild dilatation of lateral ventricles is seen. (b) T2 axial section of the brain showing a heterogeneously hyperintense lesion in the third ventricle. Multiple intratumoral cysts resembling “soap bubble” are seen. (c) Sagittal section of brain on contrast study showing intense enhancement of the solid part of the lesion The patient was operated with right frontoparietal craniotomy using the anterior interhemispheric transcallosal approach. Corpus callosotomy of around 2 cm was done the choroid plexus was seen and followed to reach the foramen of Monro, and the tumor was approached transforaminally. Total removal of the tumor was achieved by piecemeal excision through the foramen of Monro. Watertight dural closure was done using Vicryl 4-0. Bone flap was replaced, and wound was closed in layers after achieving absolute hemostasis. Intraoperatively, the tumor was found to be globular, pale, grayish-white, soft, suckable, and moderately vascular. The tumor sample was sent for histopathologic examination and immunohistochemistry (synaptophysin and neuron-specific enolase [NSE]). On histopathology [Figure 2a], small sheets of atypical round-/oval-/epithelial-like cells with enlarged round/oval/hyperchromatic nuclei with occasional nucleoli with definite cellular-nuclear pleomorphism were seen, and rare mitotic activity was noted. On immunohistochemistry [Figure 2b and c], both synaptophysin and NSE were positive helping us to arrive at the diagnosis of central neurocytoma.
Figure 2

(a) Histopathologic examination suggesting degenerated cellular neoplasm with definite cytologic atypia corresponding to the WHO grade II tumor. (b) Synaptophysin positive. (c) Neuron-specific enolase positive

(a) Histopathologic examination suggesting degenerated cellular neoplasm with definite cytologic atypia corresponding to the WHO grade II tumor. (b) Synaptophysin positive. (c) Neuron-specific enolase positive The patient was discharged without any neurological deficits and with relief of headache on the 10th postoperative day. Till date, the patient is on regular follow-up with us clinico-radiologically.

Discussion

Central neurocytoma was described in 1982 by Hassoun et al.[4] The incidence of central neurocytoma is only 0.25%–0.5% of all brain tumors.[5] Initially, it was termed as a WHO grade I tumor and was updated to grade II in 1993.[6] Characteristically, they are located in the ventricular regions supratentorially. Fifty percent are located in the lateral ventricles, 13% in both lateral and third ventricles, and solitary third ventricle central neurocytomas amount to only 3%.[7] Classically, central neurocytomas present with features of increased intracranial pressure associated with obstructive hydrocephalus. In a study, Schild et al. reviewed 27 patients of which 93% had headache, 37% had visual problems, and 30% had nausea and vomiting as their chief complaints,[8] which was similar to the complaints of our patient. The most commonly used approaches are anterior transcallosal approach and anterior transcortical approach.[9] In our case, the previous approach, i.e., the anterior transcallosal approach was done. Central neurocytoma is confirmed diagnostically by immunohistochemistry for neuronal antigens such as synaptophysin and NSE. Among the two, synaptophysin is most remarkable and NSE is considered nonspecific.[10] Both these tests were positive in our study. Central neurocytomas generally carry a good prognosis. The ideal treatment is the total surgical removal of the tumor. Radiotherapy might prove beneficial in adult cases, in which there is incomplete tumor removal although it is still a matter of concern in children.[3]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

1.  Central neurocytomas of uncommon locations: report of two cases.

Authors:  Francinaldo Lobato Gomes; Luciano Ricardo França; Samuel Tau Zymberg; Sérgio Cavalheiro
Journal:  Arq Neuropsiquiatr       Date:  2006-12       Impact factor: 1.420

2.  Central neurocytoma: histopathological variants and therapeutic approaches.

Authors:  M G Yasargil; K von Ammon; A von Deimling; A Valavanis; W Wichmann; O D Wiestler
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

3.  Central neurocytoma. An electron-microscopic study of two cases.

Authors:  J Hassoun; D Gambarelli; F Grisoli; W Pellet; G Salamon; J F Pellissier; M Toga
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

Review 4.  From the archives of the AFIP. Cerebral intraventricular neoplasms: radiologic-pathologic correlation.

Authors:  Kelly K Koeller; Glenn D Sandberg
Journal:  Radiographics       Date:  2002 Nov-Dec       Impact factor: 5.333

5.  Central neurocytomas.

Authors:  S E Schild; B W Scheithauer; M G Haddock; D Schiff; P C Burger; W W Wong; M K Lyons
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

6.  Defining the best available treatment for neurocytomas in children.

Authors:  Dirk Rades; Steven E Schild; Fabian Fehlauer
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

Review 7.  Central neurocytoma: a synopsis of clinical and histological features.

Authors:  J Hassoun; F Söylemezoglu; D Gambarelli; D Figarella-Branger; K von Ammon; P Kleihues
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

Review 8.  From the radiologic pathology archives: intraventricular neoplasms: radiologic-pathologic correlation.

Authors:  Alice Boyd Smith; James G Smirniotopoulos; Iren Horkanyne-Szakaly
Journal:  Radiographics       Date:  2013 Jan-Feb       Impact factor: 5.333

9.  Extraventricular neurocytoma--report of a case.

Authors:  Berker Cemil; Kagan Tun; Yahya Guvenc; Ayhan Ocakcioglu; Ozlem Ozen
Journal:  Neurol Neurochir Pol       Date:  2009 Mar-Apr       Impact factor: 1.621

10.  Central neurocytoma. A clinicopathological, immunohistochemical and ultrastructural study of 7 cases.

Authors:  P Robbins; A Segal; S Narula; B Stokes; M Lee; W Thomas; P Caterina; I Sinclair; D Spagnolo
Journal:  Pathol Res Pract       Date:  1995-03       Impact factor: 3.250

  10 in total
  2 in total

1.  Tumor control of third ventricular central neurocytoma after gamma knife radiosurgery in an elderly patient: A case report and literature review.

Authors:  Sue-Jee Park; Tae-Young Jung; Seul-Kee Kim; Kyung-Hwa Lee
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

2.  The role of methylation profiling in histologically diagnosed neurocytoma: a case series.

Authors:  Adam Z Kalawi; Denise M Malicki; Zied Abdullaev; Drew W Pratt; Martha Quezado; Kenneth Aldape; Jennifer D Elster; Megan R Paul; Paritosh C Khanna; Michael L Levy; John R Crawford
Journal:  J Neurooncol       Date:  2022-08-22       Impact factor: 4.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.